Judith Klimovsky

2.4k total citations · 1 hit paper
27 papers, 1.9k citations indexed

About

Judith Klimovsky is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Judith Klimovsky has authored 27 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 9 papers in Epidemiology and 5 papers in Molecular Biology. Recurrent topics in Judith Klimovsky's work include Cancer Treatment and Pharmacology (10 papers), Lung Cancer Research Studies (10 papers) and Neuroendocrine Tumor Research Advances (9 papers). Judith Klimovsky is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Lung Cancer Research Studies (10 papers) and Neuroendocrine Tumor Research Advances (9 papers). Judith Klimovsky collaborates with scholars based in United States, Switzerland and Germany. Judith Klimovsky's co-authors include David Lebwohl, Edward M. Wolin, Valentine Jehl, James C. Yao, Éric Baudin, John D. Hainsworth, Marianne Pavel, Marc Peeters, Kjell Öberg and Robert Winkler and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Judith Klimovsky

27 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

2011 767 citations Marianne Pavel, John D. Hainsworth et al. The Lancet profile →

Peers

Countries citing papers authored by Judith Klimovsky

Since Specialization

Citations

This map shows the geographic impact of Judith Klimovsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith Klimovsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith Klimovsky more than expected).

Fields of papers citing papers by Judith Klimovsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith Klimovsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith Klimovsky. The network helps show where Judith Klimovsky may publish in the future.

Co-authorship network of co-authors of Judith Klimovsky

This figure shows the co-authorship network connecting the top 25 collaborators of Judith Klimovsky. A scholar is included among the top collaborators of Judith Klimovsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith Klimovsky. Judith Klimovsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison 2013 ·Experimental Hematology and Oncology ·James Signorovitch, Elyse Swallow, Evan Kantor, Xufang Wang, Judith Klimovsky, T Haas, Beth Devine, Peter Metrakos	33
2	Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors 2013 ·CHEST Journal ·Nicola Fazio, Donald Granberg, Ashley Grossman, Stephen Saletan, Judith Klimovsky, Ashok Panneerselvam, Edward M. Wolin	94
3	Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases 2013 ·Annals of the New York Academy of Sciences ·David Lebwohl, Özlem Anak, Tarek Sahmoud, Judith Klimovsky, (unknown), T Haas, Joseph A. Posluszny, Stephen Saletan, William J. Berg	68
4	Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer 2012 ·Journal of Thoracic Oncology ·Vassiliki A. Papadimitrakopoulou, Jean‐Charles Soria, Annette Jappe, Valentine Jehl, Judith Klimovsky, Bruce E. Johnson	28
5	Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET). 2012 ·Journal of Clinical Oncology ·James C. Yao, John D. Hainsworth, Edward M. Wolin, Marianne Pavel, Éric Baudin, David J. Gross, Philippe Ruszniewski, Paola Tomassetti, Ashok Panneerselvam, Stephen Saletan, Judith Klimovsky	20
6	Updated safety results from EXIST-2: Everolimus therapy for angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sLAM). 2012 ·Journal of Clinical Oncology ·John J. Bissler, Christopher Kingswood, Bernard A. Zonnenberg, Michael Frost, Elena Belousova, Elżbieta Radzikowska, Matthias Sauter, Norio Nonomura, (unknown), Petrus de Vries, Judith Klimovsky, Gaurav Shah, Sara Miao, Jeremie Lincy, Klemens Budde	1
7	Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET). 2012 ·Journal of Clinical Oncology ·James C. Yao, John D. Hainsworth, Edward M. Wolin, Marianne Pavel, Éric Baudin, David J. Gross, Philippe Ruszniewski, Paola Tomassetti, Ashok Panneerselvam, Stephen Saletan, Judith Klimovsky	10
8	Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib. 2012 ·Blood ·Michael Wang, Leslie Popplewell, Robert H. Collins, Jane N. Winter, André Goy, Anna Robeva, Nicoletta Pirotta, (unknown), Judith Klimovsky, Owen A. O’Connor	1
9	Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study breakdown → 2011 ·The Lancet ·Marianne Pavel, John D. Hainsworth, Éric Baudin, Marc Peeters, Dieter Hörsch, Robert Winkler, Judith Klimovsky, David Lebwohl, Valentine Jehl, Edward M. Wolin, Kjell Öberg, Eric Van Cutsem, James C. Yao	767
10	Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2). 2011 ·Journal of Clinical Oncology ·James C. Yao, John D. Hainsworth, Éric Baudin, Marc Peeters, Dieter Hoersch, Lowell Anthony, Judith Klimovsky, (unknown), Valentine Jehl, Marianne Pavel	18
11	Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial. 2011 ·Journal of Clinical Oncology ·Lowell Anthony, Marc Peeters, John D. Hainsworth, Éric Baudin, Dieter Hoersch, Judith Klimovsky, (unknown), Valentine Jehl, Marianne Pavel, James C. Yao	4
12	Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). 2010 ·Journal of Clinical Oncology ·N. B. Leighl, Jean‐Charles Soria, Jaafar Bennouna, Normand Blais, Anne M. Traynor, V. Papadimitrakopoulou, Judith Klimovsky, Annette Jappe, Valentine Jehl, B. E. Johnson	15
13	Phase I/II Study of Ixabepilone plus Capecitabine in Anthracycline–Pretreated/Resistant and Taxane-Resistant Metastatic Breast Cancer 2008 ·Clinical Breast Cancer ·Craig A. Bunnell, Linda T. Vahdat, Lee S. Schwartzberg, Julie R. Gralow, Judith Klimovsky, Valerie Poulart, Ronald Peck, Eva Thomas	48
14	Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer 2007 ·Journal of Clinical Oncology ·Eva Thomas, Josep Tabernero, Monica Fornier, Pierfranco Conté, P. Fumoleau, Aňa Lluch, Linda T. Vahdat, Craig A. Bunnell, Howard A. Burris, Patrice Viens, José Baselga, Edgardo Rivera, Valentina Guarneri, Valerie Poulart, Judith Klimovsky, David Lebwohl, Miguel Martín	226
15	Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment 2007 ·Journal of Clinical Oncology ·E. Donnall Thomas, Henry Gómez, Rubi K. Li, Hyun Cheol Chung, Luis Fein, Valorie F. Chan, Jacek Jassem, Xavier Pivot, Judith Klimovsky, (unknown), Binghe Xu, Mario Campone, Guillermo Lerzo, (unknown), P. Mukhopadhyay, Linda T. Vahdat, Henri Roché	383
16	Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors 2007 ·Cancer Chemotherapy and Pharmacology ·Toshio Shimizu, Noboru Yamamoto, Yasuhide Yamada, Yasuhito Fujisaka, Kazuhiko Yamada, Yutaka Fujiwara, Kyoko Takayama, Takuto Tokudome, Judith Klimovsky, Tomohide Tamura	28
17	Phase II study of ixabepilone in patients (pts) with taxane-resistant metastatic breast cancer (MBC): Final report 2006 ·Journal of Clinical Oncology ·Pierfranco Conté, E. Donnall Thomas, (unknown), Judith Klimovsky, Josep Tabernero	15
18	Manageable safety profile in patients with taxane-resistant metastatic breast cancer (MBC) treated with ixabepilone: Final report 2006 ·Journal of Clinical Oncology ·Monica Fornier, (unknown), Judith Klimovsky, Craig A. Bunnell	3
19	Phase I study of BMS-247550 (ixabepilone) given every 3 weeks in Japanese patients with refractory solid tumors 2005 ·Journal of Clinical Oncology ·T. Shimizu, Norio Yamamoto, Yasuhito Fujisaka, Yuki Yamada, Tohru Sakamoto, Koichi Takayama, M. Hirose, Tomohiro Tamura, Takuto Tokudome, Judith Klimovsky	3
20	Nodal T Cell Blast Crisis in Chronic Myeloid Leukemia 2000 ·Leukemia & lymphoma ·(unknown), Vladimir B. Birman, (unknown), (unknown), (unknown), (unknown), (unknown), Judith Klimovsky, Benjamín Koziner	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact